Dr. Vince Clinical Research Revenue and Competitors

Location

N/A

Total Funding

Employee Data

  • Dr. Vince Clinical Research has 93 Employees.(i)
  • Dr. Vince Clinical Research grew their employee count by 69% last year.

Dr. Vince Clinical Research's People

NameTitleEmail/Phone
1
CEO and Medical DirectorReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
VP, Business DevelopmentReveal Email/Phone
4
EVP, Scientific AffairsReveal Email/Phone
5
Director, Business DevelopmentReveal Email/Phone
6
Executive Director, Clinical Trial ServicesReveal Email/Phone
7
Director, Sleep Research / Director, TrainingReveal Email/Phone
8
Senior Director, Clinical OperationsReveal Email/Phone
9
Director, Clinical Trial ServicesReveal Email/Phone
10
Director PharmacyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A4826%N/AN/A
#2
N/A6836%N/AN/A
#3
N/A9369%N/AN/A
Add Company

What Is Dr. Vince Clinical Research?

Dr. Vince Clinical Research (DVCR) is a world-class early phase CRO (Contract Research Organization) with a custom-built, green-designed headquarters and research complex encompassing three buildings in Overland Park, KS. DVCR’s complex includes a 90-bed clinical pharmacology unit featuring a combination of luxurious and private research suites and a GMP compliant pharmacy. DVCR specializes in conducting clinical trials for both healthy normal volunteers and patient populations in a wide variety of early phase trials. Support services include project management, data management, biostatistics, monitoring and medical writing. By leveraging both technology and one of the country’s most experienced leadership teams, DVCR provides Smarter, Faster Data to their biopharmaceutical clients.

keywords:N/A

N/A

Total Funding

93

Number of Employees

N/A

Revenue (est)

69%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.3M938%N/A
#2
$18.9M9415%N/A
#3
$23.9M9432%N/A
#4
$13.8M95-4%N/A
#5
$14.3M9544%N/A